Skip Navigation

Annals of Oncology 2009 20(Supplement 4):iv76-iv78; doi:10.1093/annonc/mdp135
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Horwich, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Horwich, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

ESMO clinical recommendations

Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

A. Horwich1, C. Parker1, V. Kataja2 and On behalf of the ESMO Guidelines Working Group*

1 Department of Clinical Oncology, Royal Marsden Hospital, Sutton, UK
2 Department of Oncology, Vaasa Central Hospital, Vaasa and Kuopio University, Kuopio, Finland

* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail clinicalrecommendations@esmo.org

The first 10% of the full text of this article appears below.


   incidence and mortality
 
The crude annual incidence of prostate cancer in the European Union (EU) is 78.9/100 000 men. It is the most common cancer in men. The mortality in the EU is 30.6/100 000 men/year. Though the incidence and survival rates vary widely between different EU States, mortality rates are similar.

Subclinical prostate cancer is common in men >50 years. Screening of healthy men using prostate-specific antigen (PSA) testing increases the incidence and leads . . . [Full Text of this Article]


   diagnosis
 

   staging and risk assessment
 

   treatment
 
localized disease (T1–2 N0/X M0/X)
locally advanced disease (T3–4 N0/X M0/X)
metastatic disease

   note
 

   funding
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?